Topline results for Regeneron Pharmaceuticals Inc.'sinjectable VEGF inhibitor Eylea in the Phase III PANORAMA study of diabetic retinopathy without edema pave the way for the drug to match US FDA labeling of Roche's competing Lucentis in this indication, yet the commercial value is unclear.
Eylea (aflibercept), which is partnered in Europe with Bayer AG, has been approved since 2011 in the US, where...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?